Molecular mechanisms of lipid-induced insulin resistance in muscle, liver and vasculature

Diabetes, Obesity and Metabolism

Volumn 7, Issue 6, 2005, Pages 621-632

  Krebs, M ^a   Roden, Michael ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b HANUSCH HOSPITAL   (Austria)

Author keywords

Cardiovascular disease; Endothelial cells; Insulin action; Intrahepatic fat content; Intramyocellular triglycerides; Non esterified fatty acids; Plasminogen activator inhibitor; Protein kinase C

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADENYLATE KINASE; CARNITINE PALMITOYLTRANSFERASE; CERAMIDE DERIVATIVE; DIACYLGLYCEROL; FATTY ACID; GLUCOSE; GLUCOSE 6 PHOSPHATE; GLUTAMINE FRUCTOSE 6 PHOSPHATE AMINOTRANSFERASE; GLYCEROL; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; LEPTIN; MALONYL COENZYME A; METFORMIN; NICOTINIC ACID DERIVATIVE; NITRIC OXIDE; PALMITOYL COENZYME A HYDROLASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; SALICYLIC ACID; TRIACYLGLYCEROL; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ADIPOSE TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BODY FAT; CELL STIMULATION; DISEASE ASSOCIATION; DISEASE CONTROL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; FAT CONTENT; FAT INTAKE; FATTY ACID BLOOD LEVEL; FATTY LIVER; FIBRINOLYSIS; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPID OXIDATION; LIPID STORAGE; LIPODYSTROPHY; LIPOLYSIS; LIVER METABOLISM; METABOLITE; MUSCLE METABOLISM; MUSCLE MITOCHONDRION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN DEFICIENCY; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

EID: 27744599788     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2004.00439.x     Document Type: Review

References (138)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-1431.
2. Eyre H, Kahn R, Robertson R et al. Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. CA Cancer J Clin 2004; 54: 190-207.
3. Hu FB, Manson JE, Stampfer MJ et al. Diet, lifestyle and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001; 345: 790-797.
4. Tuomilehto J, Lindström J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.
5. Group DPPR. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Eng] J Med 2002; 346: 393-403.
6. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
7. Reaven GM, Hollenbeck C, Jeng CY, Wu MS, Chen YDI. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 1988; 37: 1020-1024.
8. Baldweg SE, Golay A, Natali A, Balkau B, Del Prato S, Coppack SW. Insulin resistance, lipid and fatty acid concentrations in 867 healthy Europeans. European group for the study of insulin resistance (EGIR). Eur J Clin Invest 2000; 30: 45-52.
9. Perseghin G, Ghosh S, Gerow K, Shulman GI. Metabolic defects in lean nondiabetic offspring of NIDDM parents. Diabetes 1997; 46: 1001-1009.
10. Oakes ND, Cooney GJ, Camilleri S, Chrisholm DJ, Kraegen EW. Mechanisms of liver and muscle insulin resistance induced by chronic high-fat feeding. Diabetes 1997; 46: 1768-1774.
11. Agus MS, Swain JF, Larson CL, Eckert EA, Ludwig DS. Dietary composition and physiologic adaptations to energy restriction. Am J Clin Nutr 2000; 71: 901-907.
12. Bachmann OP, Dahl DB, Brechtel K et al. Effects of intravenous an dietary lipid challenge on intramyocellular lipid content and the relation with insulin sensitivity in humans. Diabetes 2001; 50: 2579-2584.
13. Krebs M, Roden M. Nutrient-induced insulin resistance in human skeletal muscle. Curr Med Chem 2004; 11: 1241-1253.
14. Krebs M, Krssak M, Bernroider E et al. Mechanism of amino acid-induced skeletal muscle insulin resistance in humans. Diabetes 2002; 51: 599-605.
15. Waldhäusl W, Roden M. The effects of free fatty acids on glucose transport and phosphorylation in human skeletal muscle. Curr Opin Endocrinol Diabetes 2000; 7: 211-216.
16. Roden M, Price TB, Perseghin G et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 1996; 97: 2859-2865.
17. Kashyap S, Belfort R, Gastaldelli A et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 2003; 52: 2461-2474.
18. Boden G, Carnell LH. Nutritional effects of fat on carbohydrate metabolism. Best Pract Res Clin Endocrinol Metab 2003; 17: 399-410.
19. DeFronzo R. The triumvirate: B-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 1988; 37: 667-687.
20. Shulman G, Rothman D, Jue T, Stein P, DeFronzo R, Shulman R. Quantification of muscle glycogen synthesis in normal subjects and subjects with non-insulin dependent diabetes by C-13 nuclear magnetic resonance spectroscopy. N Engl J Med 1990; 322: 223-228.
21. Roden M, Shulman GI. Applications of NMR spectroscopy to study muscle glycogen metabolism in man. Annu Rev Med 1999; 50: 277-290.
22. Krebs M, Krssak M, Nowotny P et al. Free fatty acids inhibit the glucose-stimulated increase of intramuscular glucose-6-phosphate concentration in humans. J Clin Endocrinol Metab 2001; 86: 2153-2160.
23. Roden M, Krssak M, Stingl H et al. Rapid impairment of skeletal muscle glucose transport/phosphorylation by free fatty acids in humans. Diabetes 1999; 48: 358-364.
24. Dresner A, Laurent D, Marcucci M et al. Effects of free fatty acids on glucose transport and IRS-1- associated phosphatidylinositol 3-kinase activity. J Clin Invest 1999; 103: 253-259.
25. Hawkins M, Tonelli J, Kishore P et al. Contribution of elevated free fatty acid levels to the lack of glucose effectiveness in type 2 diabetes. Diabetes 2003; 52: 2748-2758.
26. Randle PJ, Hales CN, Garland PB, Newsholme EA. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963; I: 785-789.
27. Cline GW, Petersen KF, Krssak M et al. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med 1999; 341: 240-246.
28. 1H NMR spectroscopy study. Diabetologia 1999; 42: 113-116.
29. Pan DA, Lillioja S, Kriketos AD et al. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes 1997; 46: 983-988.
30. 13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 1999; 48: 1600-1606.
31. 1H spectroscopy: validation in vivo. Am J Physiol 1999; 276: E977-E989.
32. Greco AV, Mingrone G, Giancaterini A et al. Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion. Diabetes 2002; 51: 144-151.
33. Anderwald C, Bernroider E, Krssak M et al. Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle. Diabetes 2002; 51: 3025-3032.
34. Goodpaster BH, He J, Watkins S, Kelley DE. Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes. J Clin Endocrinol Metab 2001; 86: 5755-5761.
35. Thamer C, Machann J, Bachmann O et al. Intramyocellular lipids: anthropometric determinants and relationships with maximal aerobic capacity and insulin sensitivity. J Clin Endocrinol Metab 2003; 88: 1785-1791.
36. Yu C, Chen Y, Cline GW et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 2002; 277: 50230-50236.
37. Ellis BA, Poynten A, Lowy AJ et al. Long-chain acyl-CoA esters as indicators of lipid metabolism and insulin sensitivity in rat and human muscle. Am J Physiol 2000; 279: E554-E560.
38. Houmard JA, Tanner CJ, Yu C et al. Effect of weight loss on insulin sensitivity and intramuscular long-chain fatty acyl-CoAs in morbidly obese subjects. Diabetes 2002; 51: 2959-2963.
39. Schmitz-Peiffer C, Craig DL, Biden TJ. Ceramide generation is sufficient to account for the inhibition of the insulin-stimulated PKB pathway in C2C12 skeletal muscle cells pretreated with palmitate. J Biol Chem 1999; 274: 24202-24210.
40. Adams JM II, Pratipanawatr T, Berria R et al. Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 2004; 53: 25-31.
41. Weigert C, Klopfer K, Kausch C et al. Palmitate-induced activation of the hexosamine pathway in human myotubes: increased expression of glutamine: fructose-6-phosphate aminotransferase. Diabetes 2003; 52: 650-656.
42. Hawkins M, Barzilai N, Liu R, Hu M, Chen W, Rosetti L. Role of the glucosamine pathway in fat-induced insulin resistance. J Clin Invest 1997; 99: 2173-2182.
43. Choi CS, Lee FN, Youn JH. Free fatty acids induce peripheral insulin resistance without increasing muscle hexosamine pathway product levels in rats. Diabetes 2001; 50: 418-424.
44. Borkman M, Storlien LH, Pan DA, Jenkins AB, Chrisholm DJ, Campbell LV. The relation between insulin sensitivity and the fatty-acid composition of skeletal muscle phospholipids. N Engl J Med 1993; 328: 238-244.
45. Clore JN, Li J, Gill R et al. Skeletal muscle phosphatidylcholine fatty acids and insulin sensitivity in normal humans. Am J Physiol 1998; 275: E665-E670.
46. 2. J Biol Chem 1996; 271: 1138-1144.
47. Shepherd PR, Kahn BB. Implications for insulin resistance and diabetes mellitus. N Engl J Med 1999; 341: 248-257.
48. Hajri T, Han XX, Bonen A, Abumrad NA. Defective fatty acid uptake modulates insulin responsiveness and metabolic responses to diet in CD36-null mice. J Clin Invest 2002; 109: 1381-1389.
49. Kim JK, Gimeno RE, Higashimori T et al. Inactivation of fatty acid transport protein 1 prevents fat-induced insulin resistance in skeletal muscle. J Clin Invest 2004; 113: 756-763.
50. Kelley DE, Mandarino LJ. Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes 2000; 49: 677-683.
51. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004; 350: 664-671.
52. Petersen KF, Befroy D, Dufour S et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003; 300: 1140-1142.
53. Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 2002; 51: 2944-2950.
54. Jerusalem F, Engel AG, Peterson HA. Human muscle fiber fine structure: morphometric data on controls. Neurology 1975; 25: 127-134.
55. He J, Watkins S, Kelley DE. Skeletal muscle lipid content and oxidative enzyme activity in relation to muscle fiber type in type 2 diabetes and obesity. Diabetes 2001; 50: 817-823.
56. Rasmussen BB, Holmback UC, Volpi E, Morio-Liondore B, Paddon-Jones D, Wolfe RR. Malonyl coenzyme A and the regulation of functional carnitine palmitoyltransferase-1 activity and fat oxidation in human skeletal muscle. J Clin Invest 2002; 110: 1687-1693.
57. McGarry JD. Banting Lecture 2001: Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002; 51: 7-18.
58. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001; 414: 799-806.
59. Kahn BB. Glucose transport: pivotal step in insulin action. Diabetes 1996; 45: 1644-1654.
60. Kruszynska YT, Worrall DS, Ofrecio J, Frias JP, Macaraeg G, Olefsky JM. Fatty acid-induced insulin resistance: decreased muscle PI3K activation but unchanged Akt phosphorylation. J Clin Endocrinol Metab 2002; 87: 226-234.
61. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000; 106: 171-176.
62. Itani SI, Ruderman NB, Schmieder F, Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkB-α. Diabetes 2002; 51: 2005-2011.
63. Griffin ME, Marcucci MJ, Cline GW et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C θ and alterations in the insulin signaling cascade. Diabetes 1999; 48: 1270-1274.
64. Tripathy D, Mohanty P, Dhindsa S et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 2003; 52: 2882-2887.
65. Marette A. Mediators of cytokine-induced insulin resistance in obesity and other inflammatory settings. Curr Opin Clin Nutr Metab Care 2002; 5: 377-383.
66. Kim JK, Kim Y-J, Fillmore JJ et al. Prevention of fat induced insulin resistance by salicylate. J Clin Invest 2001; 108: 437-446.
67. Lillioja S, Mott DM, Spraul M et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 1993; 329: 1988-1992.
68. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med 1990; 113: 909-915.
69. Inzucchi SE, Maggs DG, Spollett GR et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 338: 867-872.
70. Maggs DG, Buchanan TA, Burant CF et al. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 176-185.
71. Petersen KF, Krssak M, Inzucchi S, Cline GW, Dufour S, Shulman GI. Mechanism of troglitazone action in type 2 diabetes. Diabetes 2000; 49: 827-831.
72. Mayerson AB, Hundal RS, Dufour S et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002; 51: 797-802.
73. Furnsinn C, Waldhausl W. Thiazolidinediones: metabolic actions in vitro. Diabetologia 2002; 45: 1211-1223.
74. Ciaraldi TP, Cha BS, Park KS, Carter L, Mudaliar SR, Henry RR. Free fatty acid metabolism in human skeletal muscle is regulated by PPARgamma and RXR agonists. Ann N Y Acad Sci 2002; 967: 66-70.
75. Luquet S, Lopez-Soriano J, Holst D et al. Peroxisome proliferator-activated receptor {delta} controls muscle development and oxidative capability. Faseb J 2003; 17: 2299-2301.
76. Wang YX, Lee CH, Tiep S et al. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 2003; 113: 159-170.
77. Perseghin G, Price T, Petersen K et al. Increased glucose transport-phosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subjects. N Engl J Med 1996; 335: 1357-1362.
78. Krssak M, Petersen KF, Bergeron R et al. Intramuscular glycogen and intramyocellular lipid utilization during prolonged exercise and recovery in man: a 13C and 1H nuclear magnetic resonance spectroscopy study. J Clin Endocrinol Metab 2000; 85: 748-754.
79. Jeukendrup AE. Regulation of fat metabolism in skeletal muscle. Ann N Y Acad Sci 2002; 967: 217-235.
80. Yuan M, Konstantopoulos N, Lee J et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science 2001; 293: 1673-1677.
81. Hundal RS, Petersen KF, Mayerson AB et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002; 109: 1321-1326.
82. Aljada A, Garg R, Ghanim H et al. Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action? J Clin Endocrinol Metab 2001; 86: 3250-3256.
83. Ghanim H, Garg R, Aljada A et al. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 2001; 86: 1306-1312.
84. Rohl M, Pasparakis M, Baudler S et al. Conditional disruption of IkappaB kinase 2 fails to prevent obesity-inducedinsulin resistance. J Clin Invest 2004; 113: 474-481.
85. Ekberg K, Landau BR, Wajngot A et al. Contributions by kidney and liver to glucose production in the post-absorptive state and after 60 h of fasting. Diabetes 1999; 48: 292-298.
86. DeFronzo RA. The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37: 667-687.
87. Roden M, Bernroider E. Hepatic glucose metabolism in humans - its role in health and disease. Best Pract Res Clin Endocrinol Metab 2003; 17: 365-383.
88. Handal RS, Krssak M, Dufour S et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000; 49: 2063-2069.
89. Magnusson I, Rothman D, Katz L, Shulman R, Shulman G. Increased rate of gluconeogenesis in type II diabetes mellitus: C-13 nuclear magnetic resonance study. J Clin Invest 1992; 90: 1323-1327.
90. Brehm A, Krssak M, Anderwald C et al. Hepatic glucose metabolism in type 2 diabetes after mixed meal ingestion. Diabetologia 2002; 45 (Suppl. 2): A188.
91. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002; 87: 3023-3028.
92. Ryysy L, Hakkinen AM, Goto T et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000; 49: 749-758.
93. Kim SP, Ellmerer M, Van Citters GW, Bergman RN. Primacy of hepatic insulin resistance in the development of the metabolic syndrome induced by an isocaloric moderate-fat diet in the dog. Diabetes 2003; 52: 2453-2460.
94. Mulhall BP, Ong JP, Younossi ZM. Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol 2002; 17: 1136-1143.
95. Roden M, Anderwald C, Furnsinn C, Waldhausl W, Lohninger A. Effects of short-term leptin exposure on triglyceride deposition in rat liver. Hepatology 2000; 32: 1045-1049.
96. Rajala MW, Obici S, Scherer PE, Rossetti L. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest 2003; 111: 225-230.
97. Stefan N, Stumvoll M, Vozarova B et al. Plasma adiponectin and endogenous glucose production in humans. Diabetes Care 2003; 26: 3315-3319.
98. Bajaj M, Suraamornkul S, Piper P et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in Pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 2004; 89: 200-206.
99. Boden G, Cheung P, Stein TP, Kresge K, Mozzoli M. FFA cause hepatic insulin resistance by inhibiting insulin suppression of glycogenolysis. Am J Physiol Endocrinol Metab 2002; 283: E12-E19.
100. Bergman RN. Non-esterified fatty acids and the liver. Why is insulin secreted into the portal vein? Diabetologia 2000; 43: 946-952.
101. Bergman RN, Bradley DC, Ader M. On insulin action in vivo: the single gateway hypothesis. Adv Exp Med Biol 1993; 334: 181-198.
102. Stingl H, Krssak M, Krebs M et al. Lipid-dependent control of hepatic glycogen stores in healthy humans. Diabetologia 2001; 44: 48-54.
103. Roden M, Stingl H, Chandramouli V et al. Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans. Diabetes 2000; 49: 701-707.
104. Chen X, Iqbal N, Boden G. The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects. J Clin Invest 1999; 103: 365-372.
105. Hawkins M, Gabriely I, Wozniak R, Reddy K, Rossetti L, Shamoon H. Glycemic control determines hepatic and peripheral glucose effectiveness in type 2 diabetic subjects. Diabetes 2002; 51: 2179-2189.
106. Mevorach M, Giacca A, Aharon Y, Hawkins M, Shamoon H, Rossetti L. Regulation of endogenous glucose production by glucose per se is impaired in type 2 diabetes mellitus. J Clin Invest 1998; 102: 744-753.
107. Lam TK, Yoshii H, Haber CA et al. Free fatty acid-induced hepatic insulin resistance: a potential role for protein kinase C-delta. Am J Physiol Endocrinol Metab 2002; 283: E682-E691.
108. Leverve XM, Guigas B, Detaille D et al. Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. Diabetes Metab 2003; 29: 6S88-94.
109. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000; 6: 998-1003.
110. Petersen KF, Oral EA, Dufour S et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002; 109: 1345-1350.
111. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial Infarction. N Engl J Med 1998; 339: 229-234.
112. Manson JE, Willett WC, Stampfer MJ et al. Body weight and mortality among women. N Engl J Med 1995; 333: 677-685.
113. Laakso M. Insulin resistance and coronary heart disease. Curr Opin Lipidol 1996; 7: 217-226.
114. Polak K, Schmetterer L, Luksch A et al. Free fatty acids/triglycerides increase ocular and subcutaneous blood flow. Am J Physiol Regul Integr Comp Physiol 2001; 280: R56-R61.
115. Steinberg HO, Tarshoby M, Monestel R et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 1997; 100: 1230-1239.
116. Steinberg HO, Baron AD. Vascular function, insulin resistance and fatty acids. Diabetologia 2002; 45: 623-634.
117. Inoguchi T, Li P, Umeda F et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000; 49: 1939-1945.
118. Dichtl W, Nilsson L, Goncalves I et al. Very low-density lipoprotein activates nuclear factor-kappaB in endothelial cells. Circ Res 1999; 84: 1085-1094.
119. Artwohl M, Roden M, Waldhausl W, Freudenthaler A, Baumgartner-Parzer SM. Free fatty acids trigger apoptosis and inhibit cell cycle progression in human vascular endothelial cells. Faseb J 2003; 18: 146-148.
120. Binder BR, Christ G, Gruber F et al. Plasminogen activator inhibitor 1: physiological and pathophysiological roles. News Physiol Sci 2002; 17: 56-61.
121. Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-1563.
122. Eitzman DT, Westrick RJ, Xu Z, Tyson J, Ginsburg D. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood 2000; 96: 4212-4215.
123. Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemost 1993; 70: 138-143.
124. Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997; 78: 656-660.
125. Calles-Escandon J, Mirza SA, Sobel BE, Schneider DJ. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes 1998; 47: 290-293.
126. Krebs M, Geiger M, Polak K et al. Increased plasma levels of plasminogen activator inhibitor-1 and soluble vascular cell adhesion molecule after triacylglycerol infusion in man. Thromb Haemost 2003; 90: 422-428.
127. Ma LJ, Mao SL, Taylor KL et al. Prevention of obesity insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004; 53: 336-346.
128. Dichtl W, Stiko A, Eriksson P et al. Oxidized LDL and lysophosphatidylcholine stimulate plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999; 19: 3025-3032.
129. Pleiner J, Schaller G, Mittermayer F, Bayerle-Eder M, Roden M, Wolzt M. FFA-induced endothelial dysfunction can be corrected by vitamin C. J Clin Endocrinol Metab 2002; 87: 2913-2917.
130. Steer P, Millgard J, Basu S et al. Vitamin C, diclophenac, and L-arginine protect endothelium-dependent vasodilation against elevated circulating fatty acid levels in humans. Atherosclerosis 2003; 168: 65-72.
131. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ 1997; 314: 1512-1515.
132. Malmberg K, Ryden L, Efendic S et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995; 26: 57-65.
133. Jain SK, Nagi DK, Slavin BM, Lumb PJ, Yudkin JS. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control. Diabet Med 1993; 10: 27-32.
134. Chaudhuri A, Janicke D, Wilson MF et al. Anti-inflammatory and profibrinolytic effect of insulin in acute ST-segment-elevation myocardial infarction. Circulation 2004; 109: 849-854.
135. Mavri A, Stegnar M, Krebs M, Sentocnik JT, Geiger M, Binder BR. Impact of adipose tissue on plasma plasminogen activator inhibitor-1 in dieting obese women. Arterioscler Thromb Vasc Biol 1999; 19: 1582-1587.
136. Fonseca VA, Reynolds T, Hemphill D et al. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications 1998; 12: 181-186.
137. Ehrmann DA, Schneider DJ, Sobel BE et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82: 2108-2116.
138. Krysiak R, Okopien B, Herman Z. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs 2003; 63: 1821-1854.